Organization: NUCRYST Pharmaceuticals Corp

Westaim puts iFire subsidiary up for sale

Cash-strapped Westaim Corp, Calgary, is seeking a buyer for its iFire Technology Corp subsidiary, a developer of flat panel television technology. Once sold, it will leave NUCRYST Pharmaceuticals Corp as its sole remain operating entity. Westaim lost $31.2 million on revenue of $20.7 million for the first nine months of 2007….

Westaim Corp reviews flagging business strategy

Westaim Corp is moving to revive its sagging fortunes with a review of its business strategy and the sale of real estate holdings in Fort Saskatchewan for a book gain of $7.5 million. The moves come as the Calgary-based firm is in danger of losing its NASDAQ listing if its stock price remains below $1…

Westaim announced IPO for NUCRYST subsidiary

Westaim Corp has announced an initial public offering (IPO) for its subsidiary NUCRYST Pharmaceuticals Corp, which develops medical products based on its nanocrystalline silver technology. The IPO is open to Canadian and US investors, with shares offered by an underwriting team led by Jeffries and Co Ltd. Westaim will retain a controlling interest in NUCRYST.

Westaim Corp slims down to focus on iFire technology

Westaim Corp, Calgary, has announced a major shake-up of its business units and replacing the head of its iFire Technology Inc subsidiary in a move designed to contain costs and focus on core assets. Michael Goldstein has been replaced as iFire’s president by Barry Heck, Westaim’s senior VP and a key player in iFire’s drive…

Westaim biomedical subsidiary moves to US

Westaim Corp subsidiary, NUCRYST Pharmaceuticals Corp (formerly Westaim Biomedical Corp), has moved its headquarters and R&D laboratories to Wakefield MA. It has also announced its intention to pursue opportunities for its silver nanocrystalline technology, the only nanotechnology of its type for healthcare applications. The decision to relocate follows successful trials and commercialization of its Acticoat-branded…